WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Entrada Therapeutics earnings were -$73.4M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest TRDA earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$43.1M, up 148.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TRDA reported annual earnings of $65.6M, with -1,081.7% growth.

TRDA earnings history

Current Revenue
$79.5M
Current Earnings
-$73.4M
Current Profit Margin
-92.3%

TRDA Return on Equity

Current Company
-17.8%
Current Industry
-9.1%
Current Market
27%
TRDA's Return on Equity (-17.8%)... subscribe to Premium to read more.
High Return on Equity Performance

TRDA undefined

Current Company
-14.6%
Current Industry
0.2%
TRDA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TRDA announces earnings.

TRDA undefined

Current Company
-17.93%
Current Industry
8.1%
TRDA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TRDA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TRDA-$73.00M-$73.35MN/A-$1.84
CLLS-$6.54M-$59.00MN/A-$0.63
TLSA-$16.62M-$11.86MN/A-$0.11
LYEL-$315.12M-$331.40MN/A-$24.29
MNPR-$17.31M-$17.31MN/A-$3.85
View Top Biotech Stocks

Entrada Therapeutics Earnings Reports & History FAQ

What were Entrada Therapeutics's earnings last quarter?

On TRDA's earnings call on Invalid Date, Entrada Therapeutics (NASDAQ: TRDA) reported Q2 2025 earnings per share (EPS) of -$1.04, up 164.6% year over year. Total TRDA earnings for the quarter were -$43.10 million. In the same quarter last year, Entrada Therapeutics's earnings per share (EPS) was $1.61.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

Is Entrada Therapeutics profitable or losing money?

As of the last Entrada Therapeutics earnings report, Entrada Therapeutics is currently losing money. Entrada Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$73.35 million, a 170.23% decrease year over year.

What was TRDA's earnings growth in the past year?

As of Entrada Therapeutics's earnings date in Invalid Date, Entrada Therapeutics's earnings has grown year over year. TRDA earnings in the past year totalled -$73.35 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.